Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Gaps In Vaccination Supplies Highlighted In Whistleblower Complaint; Will RAPID Partnership Save The Day?

Executive Summary

Ousted BARDA chief says HHS leaders ignored his warnings that the US lacks the necessary supplies of needles and syringes to administer a widespread COVID-19 vaccination campaign, and it could take the country two years to have enough supplies. A new public-private partnership announced in March is working to fill in those gaps. 

You may also be interested in...



As COVID-19 Response Capacity Loans Languish, DFC Punts GAO’s Questions About It To DOD, HHS

Loan program launched in June 2020 to strengthen domestic supply chains for COVID-19 response was deluged with applications, but has not completed any loans, and the GAO has a good idea why.

Coronavirus Notebook: Remdesivir Supply Dwindles; US FDA Signs Another RWE Deal; Corning Gets BARDA Contract For Glass Vials

Dispatches from a world turned upside down also include changes in drug sample distribution guidelines and further reductions in the hours of FDA’s COVID hotline.

Trump’s ‘Warp Speed’ Initiative Could Fund 3 to 5 Large-Scale COVID Vaccine Trials

FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel